beta
IA Trial Radar
O estudo clínico NCT05296096 (PROXIMUS) para Perda Muscular, Proteína, Mobilidade, LLA pediátrica está recrutando. Consulte a visualização em cartões do Radar de Estudos Clínicos e as ferramentas de descoberta de IA para ver todos os detalhes. Ou pergunte qualquer coisa aqui.
Um estudo corresponde aos critérios do filtro
Visualização em cartões
Voltar à pesquisa

PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS (PROXIMUS)

Recrutando
Os detalhes do estudo clínico estão disponíveis principalmente em inglês. No entanto, a IA Trial Radar pode ajudar! Basta clicar em 'Explicar o estudo' para visualizar e discutir as informações do estudo no idioma selecionado.
O estudo clínico NCT05296096 (PROXIMUS) é um ensaio intervencionista para Perda Muscular, Proteína, Mobilidade, LLA pediátrica. Seu status atual é: recrutando. O estudo começou em 20 de fevereiro de 2023 e pretende incluir 72 participantes. Coordenado por Boston Children's Hospital e deve ser concluído em 30 de junho de 2026. Essas informações foram atualizadas no ClinicalTrials.gov em 5 de janeiro de 2024.
Resumo
The investigators have designed a 2-center, pilot feasibility, randomized controlled trial (PROXIMUS) to determine the feasibility and safety of a larger multi center, randomized open-label trial comparing high protein combined with individualized exercise vs. standard management during the acute phase of critical illness in children. The investigators aim to determine the impact of the intervention on preservation of muscle mass; and functional status at 1 month and 6 months after randomization.
Descrição detalhada
Mortality in U.S. pediatric intensive care units (PICUs) is improving, resulting in an increased focus on the quality of life of survivors who often have persistent physical, cognitive, and psychological impairments. Mechanically ventilated children in particular experience immobilization and poor nutrient intake, which results in muscle loss during acute illness. Early mobility and optimal nutrition during acute critical illness have been associated with muscle mass preservation and decreased duration of mechanical ventilation. These interventions may have the potential to decrease preventable PICU-acquired morbidities. However, the optimal doses and long-term benefits of these interventions have not been shown in randomized studies of critically ill PICU patients.

Thus, the investigators will test the first pediatric-specific, inter-professional intervention that integrates high protein and individualized exercise. This intervention was developed by a team of experts in the fields of nutrition, early mobility, rehabilitative exercise, muscle ultrasound (US), and functional outcomes.

The investigators propose a 2-center, pilot feasibility, randomized controlled trial (PROXIMUS) with the following Specific Aims:

  1. To determine the feasibility and safety of a randomized open-label trial comparing high protein combined with individualized exercise vs. standard management during the acute phase of critical illness in children;
  2. To determine the impact of high protein and individualized exercise on preservation of muscle mass; and
  3. To determine the impact of high protein and individualized exercise on functional status at 1 month and 6 months after randomization.

Outcomes: The investigators will assess feasibility with a composite measure that combines predetermined thresholds for screening, enrollment, allocation, and compliance/adherence with significant separation in doses of protein and exercise between the two arms. Safety will be defined as absence of difference in rates of new renal injury and exercise related adverse events.

Preservation of muscle mass will be assessed by percent daily change in US-measured quadriceps femoris muscle thickness (QFMT) during the PICU stay. The investigators will use a validated imaging protocol with high reliability and reproducibility. The investigators will also examine the difference in the normative standard scores (T-scores) between the two arms for the Pediatric Evaluation of Disability Inventory - Computer Adaptive Test (PEDI-CAT) assessment. Other secondary outcomes are Functional Status Scale, PedsQL, and muscle quality by US.

The investigators hypothesize that a larger trial will be feasible and safe. Patients randomized to the combined intervention will have lower decline in QFMT and better scores on PEDI-CAT assessment.

If proven feasible and safe, the PROXIMUS intervention has potential to profoundly change medical care in the PICU and substantially impact public health by improving long-term outcomes for the growing number of pediatric survivors of critical illness.

Título oficial

PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS - a Pilot Feasibility, Randomized Controlled Trial

Condições
Perda MuscularProteínaMobilidadeLLA pediátrica
Publicações
Artigos científicos e trabalhos de pesquisa publicados sobre este estudo clínico:
Outros IDs do estudo
  • PROXIMUS
  • P00040737
Número NCT
NCT05296096
Data de início (real)
2023-02-20
Última atualização postada
2024-01-05
Data de conclusão (estimada)
2026-06-30
Inscrição (estimada)
72
Tipo de estudo
Intervencionista
FASE
N/A
Status
Recrutando
Palavras-chave
protein
exercise
mechanical ventilation
outcome
nutrition
Propósito principal
Cuidados de suporte
Alocação do design
Randomizado
Modelo de intervenção
Atribuição paralela
Cegamento (Mascaramento)
Simples-cego
Braços / Intervenções
Grupo de participantes/BraçoIntervenção/Tratamento
Comparador ativoStandard protein and exercise
All enrolled patients randomized to this arm will receive a baseline nutrition and nurse-driven mobility pathway and other evidence-based bundled strategies as standard of care.
Protein Dosage and Rehabilitation Team Delivered Exercise Prescription
The dietitian and rehabilitation team will be consulted on enrollment and will assess the patient for nutritional and functional status using the institutional criteria and physical exam. The study dietitian will prescribe the protein goal based on the randomization assignment and age group. For the high protein arm, protein goals will be 3g/kg/day for ages 1-1yrs, and 2.4g/kg/day for ages greater than 12 years. The rehabilitation team will determine the appropriate highest level of mobility (HLM) for the day in collaboration with the medical team on morning rounds. The rehabilitation team will prescribe passive or active participation in two 30-minute HLM sessions, individualized to their baseline function and clinical status and/or restrictions.
ExperimentalHigh protein plus exercise
High protein nutrition: To achieve the prescribed age-appropriate high protein target, dietitians will use EN preferentially, or if EN is contraindicated, PN may be used. High-protein EN formulas and/or protein supplements (powder or liquid) will be added to formula/breast milk feedings or administered separately in divided bolus doses. Dietitians routinely employ and customize these solutions in their scope of practice. When EN is insufficient to meet protein targets, PN may be prescribed to make up the deficit on or after the end of PICU day 3. Energy and protein delivery adequacy (% of prescribed goal) will be monitored daily by the study team. Patients in this arm will also be prescribed the age-appropriate highest-level of mobility by the rehabilitation team with a goal of 30 minutes duration, twice daily.
Protein Dosage and Rehabilitation Team Delivered Exercise Prescription
The dietitian and rehabilitation team will be consulted on enrollment and will assess the patient for nutritional and functional status using the institutional criteria and physical exam. The study dietitian will prescribe the protein goal based on the randomization assignment and age group. For the high protein arm, protein goals will be 3g/kg/day for ages 1-1yrs, and 2.4g/kg/day for ages greater than 12 years. The rehabilitation team will determine the appropriate highest level of mobility (HLM) for the day in collaboration with the medical team on morning rounds. The rehabilitation team will prescribe passive or active participation in two 30-minute HLM sessions, individualized to their baseline function and clinical status and/or restrictions.
Desfecho primário
Medida de desfechoDescrição da medidaPrazo
Feasibility of recruitment and adherence to study procedures
Feasibility (primary composite outcome) will be assessed by the following metrics: (1) \>80% of eligible patients are approached for consent; (2) \>35% of eligible patients are randomized (enrollment and consent); (3) \>80% of consented patients receive study treatments (allocation and adherence).
Through study completion, up to 10 days
Tolerability of protein intervention (serum creatinine change)
Incidence of treatment-related adverse events as assessed by 3-fold rise in serum creatinine or intolerance (new emesis or diarrhea) related to the study diet.
Through study completion, up to 10 days
Safety of protein (new renal injury) and exercise interventions (any associated adverse events)
Incidence of treatment-related adverse events; specifically new renal injury or injury/discomfort associated with exercise.
Through study completion, up to 10 days
Desfecho secundário
Medida de desfechoDescrição da medidaPrazo
Change in Muscle mass thickness
As assessed by the change in quadriceps femoris (QF) muscle thickness between baseline measurement and measurement on study completion.
Through study completion, up to 10 days
Functional assessment - motor, cognitive and responsibility
The investigators will administer the Pediatric Evaluation of Disability Inventory - Computer Adaptive Test (PEDI-CAT) test at 1 and 6 months after enrollment, and compare the scaled T-scores between the two trial arms at each time point. Higher score is better.
6 months
Multidimensional Pediatric Health related Quality of Life assessment (Physical, Emotional, Social, School Functioning domains) using a validated tool
The investigators will administer the Pediatric Health Related Quality of Life Questionnaire (PedsQoL) test at 1 and 6 months after enrollment, and compare the score between the two trial arms at each time point. Higher score on the developmentally appropriate questionnaire is better.
6 months
Assessment of Functional status - sensory, communication, motor, sensory and feeding
The investigators will administer the Functional Status Scale (FSS) assessment at 1 and 6 months after enrollment, and compare this scale between the two trial arms at each time point. The scale ranges from 6 to 30 points, lower is better,
6 months
Critérios de elegibilidade

Idades elegíveis
Criança
Idade mínima
1 Year
Sexos elegíveis
Todos
  1. ICU patients aged 1 year (corrected) to <18 years
  2. Require mechanical ventilation (endotracheal intubation or tracheostomy, or initiation of noninvasive ventilation) in the first 72 hours of PICU admission.
  3. Able to consent to participate within 72 hours of initiation of mechanical ventilation initiation.

  • Patients unable to receive EN, PN, or who are on a specialized diet incompatible with the study intervention
  • Fulminant liver failure
  • Kidney failure (≥KDIGO Stage 3) without replacement therapy
  • Functional Status Scale score at PICU admission <9
  • End of life/redirection of care
  • ECMO therapy
  • Continuous neuromuscular blockade and/or bedrest is medically or surgically necessitated Participation in a conflicting interventional trial
  • High risk of refeeding syndrome
  • Inborn errors of metabolism
  • High BSA burns.
Boston Children's Hospital logoBoston Children's Hospital
Responsável pelo estudo
Nilesh M. Mehta, Investigador principal, Faculty, Critical Care; Professor of Anesthesia, Boston Children's Hospital
Contato central do estudo
Contato: Nilesh M. Mehta, MD, 6173557327, [email protected]
Contato: Lori Bechard, RD, PhD, 6173557327, [email protected]
2 Locais do estudo em 1 países

Maryland

Johns Hopkins Hospital, Baltimore, Maryland, 21218, United States
Sapna Kudchadkar, MD, PhD, Contato, [email protected]
Sapna R Kudchadkar, MD, PhD, Investigador principal
Recrutando

Massachusetts

Boston Children's Hospital, Boston, Massachusetts, 02115, United States
Lori Bechard, RD, PhD, Contato, 617-355-7327, [email protected]
Nilesh Mehta, MD, Investigador principal
Recrutando